** Cancer therapy developer Kronos Bio's shares rise 4% to 90 cents premarket
** KRON to lay off about 83% of its employees by year-end
** CEO Norbert Bischofberger has stepped down after nearly six years in the role - KRON
** KRON appoints chief financial officer Deborah Knobelman as interim CEO
** As of March 11, KRON had 62 full-time employees and one part-time employee - SEC filing
** KRON had announced ~21% reduction in its workforce earlier this year
** As of last close, stock has fallen ~31% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。